Myeloproliferative Neoplasms | Topics

 
High-Dose Imetelstat Improves OS, Offers Clinical Benefit in High-Risk Myelofibrosis
December 05, 2020

The telomerase inhibitor demonstrated improved overall survival spleen response, and symptom response in patients with myelofibrosis.

Addition of Navitoclax Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis
December 05, 2020

Study results showed that adding navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

Momelotinib Sustains Long-Term Survival in Patients With Myelofibrosis
December 05, 2020

Treatment with momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.